Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers

BMC Psychiatry

Teshome Shibre³  Lars Jacobsson¹  Teferra Beyero³  Charlotte Hanlon²  Solomon Teferra³ 

[1] Division of Psychiatry, Department of Clinical Sciences, Umeå University, Umeå, Sweden;Centre for Global Mental Health, Institute of Psychiatry, King’s College London, London, UK;Department of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia

关键词: Schizophrenia;    Qualitative;    Medication;    Ethiopia;    Antipsychotic;    Adherence;   

Others  :  1124025
DOI  :  10.1186/1471-244X-13-168

 received in 2012-11-25, accepted in 2013-06-12,  发布年份 2013

【 摘 要 】

Background

Levels of non-adherence to antipsychotic medication in persons with schizophrenia in rural African settings have been shown to be comparable to those found in high-income countries. Improved understanding of the underlying reasons will help to inform intervention strategies relevant to the context.

Methods

A qualitative study was conducted among persons with schizophrenia (n = 24), their caregivers (n = 19), research field workers (n = 7) and health workers (n = 1) involved in the ongoing population-based cohort study, ‘The Butajira Study on Course and Outcome of Schizophrenia and Bipolar Disorder’, based in rural Ethiopia. Six focus group discussions and 9 in-depth interviews were conducted to elicit perspectives on non-adherence to antipsychotic medication. Thematic analysis was used to identify prominent perspectives.

Results

Predominant reasons for non-adherence specific to a low-income country setting included inadequate availability of food to counter appetite stimulation and the perceived strength of antipsychotic medications. The vital role of the family or other social support in the absence of a statutory social safety net was emphasised. Expectations of cure, rather than need for continuing care, were reported to contribute to non-adherence in the longer-term.

Many of the factors associated with non-adherence in high-income countries were also considered important in Ethiopia, including lack of insight, failure to improve with treatment, medication side effects, substance abuse, stigma and dissatisfaction with the attitude of the care provider.

Conclusion

This study identifies additional barriers to medication adherence faced by persons with schizophrenia in Ethiopia compared to those in high-income countries. In this era of scaling up of mental health care, greater attention to provision of social and financial assistance will potentially improve adherence and thereby enable patients to benefit more fully from medication.

【 授权许可】

   
2013 Teferra et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Carpenter WT, Davis JM: PERSPECTIVE: another view of the history of antipsychotic drug discovery and development. Mol Psychiatry 2012, 17:1168-1173.
• [2]Thornley B, Adams C: Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br Med J 1998, 317:1181-1184.
• [3]Teferra S, Shibre T, Fekadu A, Medhin G, Wakwoya A, Alem A, Jacobsson L: Five-year clinical course and outcome of schizophrenia in Ethiopia. Schizophr Res 2012, 136:137-142.
• [4]Teferra S, Shibre T, Fekadu A, Medhin G, Wakwoya A, Alem A, Kullgren G, Jacobsson L: Five-year mortality in a cohort of people with schizophrenia in Ethiopia. BMC Psychiatry 2011, 11:165. BioMed Central Full Text
• [5]Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D: Clinical course and outcome of schizophrenia in a predominantly treatment naïve cohort in Ethiopia. Schizophr Bull 2009, 35:646-654.
• [6]Nosé M, Barbui C, Tansella M: How often do patients with psychosis fail to adhere to treatment programs? A systematic review. Psychol Med 2003, 33:1149-1160.
• [7]Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009, 70(suppl 4):1-46.
• [8]Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
• [9]Adelufosi AO, Adebowale TO, Abayomi O, Mosanya JT: Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiat 2012, 34:72-79.
• [10]Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997, 23:637-651.
• [11]Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995, 52:173-188.
• [12]Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T: Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry 2010, 44:921-928.
• [13]Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M: Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis 2006, 194:454-457.
• [14]Barbui C, Kikkert M, Mazzi MA, Becker T, Bindaman J, Schene A, Nosè M, Helm H, Thornicroft G, Tensella M: Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology 2009, 42:311-317.
• [15]Staring AB, Mulder CL, Duivenvoorden HJ, De Haan L, Van der Gaag M: Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. Schizophr Res 2009, 113:27-33.
• [16]Breen A, Swartz L, Joska J, Flisher AJ, Corrigall J: Adherence to treatment in poorer countries: a new research direction? Psychiatr Serv 2007, 58:567-568.
• [17]Ministry of Health Federal Democratic Republic of Ethiopia: National Mental Health Strategy 2011–2015. Addis Ababa: Ethiopia MOH; 2012.
• [18]World Health Organization: Mental Health Gap Action Programme (mhGAP): Scaling up care for mental, neurological, and substance use disorders . Geneva: UN World Health Organization; 2008.
• [19]Kebede D, Alem A, Shibre T, Negash A, Fekadu A, Fekadu D, Deyassa N, Jacobsson L, Kullgren G: Onset and clinical course of schizophrenia in Butajira-Ethiopia: a community-based study. Soc Psych Psych Epid 2003, 38:625-631.
• [20]Alem A, Jacobsson L, Araya M, Kebede D, Kullgren G: How are mental disorders seen and where is help sought in a rural Ethiopian community? A key informant study in Butajira, Ethiopia. Acta Psychiatr Scnad 1999, 100:40-47.
• [21]Araya M, Mussie M, Jacobsson L: Decentralized psychiatric nursing service in Ethiopia–a model for low income countries. Ethiop Med J 2009, 47:61-64.
• [22]Kitzinger J: Qualitative Research: introducing focus groups. BMJ 1995, 311:299-302.
• [23]Kikkert MJ, Schene AR, Koeter MW, Robson D, Born A, Helm H, Nose M, Goss C, Thornicroft G, Gray RJ: Medication Adherence in Schizophrenia: Exploring Patients’, Carers’ and Professionals’ Views. Schizophr Bull 2006, 32:786-794.
• [24]Braun V, Clarke V: Using thematic analysis in psychology. Qual Res Psychol 2006, 3:77-101.
• [25]Hanlon C, Medhin G, Alem A, Tesfaye F, Lakew Z, Worku B, Dewey M, Araya M, Abdulahi A, Hughes MT, Patel V, Prince M: Impact of antenatal common mental disorders upon perinatal outcomes in Ethiopia: the P-MaMiE population-based cohort study. Trop Med Int Health 2009, 14:156-166.
• [26]Lijalem M, Tesfaye F, Alem A, Abera K, Kebede D: Nutrition status of cases of schizophrenia and bipolar disorders in Butajira, rural Ethiopia Addis Ababa. MPH Thesis: Addis Ababa University, School of Public Health; 2003.
• [27]Orthen-Gambill N, Salomon M: Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved? Pharmacol Biochem Behav 1990, 36:837-84.
• [28]Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004, 66:1-57.
• [29]Harden AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, Kglatwane J, Kinsman J, Kwasa R, Maridadi J, Moroka TM, Moyo S, Nakiyemba A, Nsimba S, Ogenyi R, Oyabba T, Temu F, Laing R: Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 2007, 19:658-665.
• [30]Au JT, Kayitenkore K, Shutes E, Karita E, Peters PJ, Tichacek A, Allen SA: Access to adequate nutrition is a major potential obstacle to antiretroviral adherence among HIV-infected individuals in Rwanda. AIDS 2006, 20:2116-2118.
• [31]Teferra S, Hanlon C, Alem A, Jacobsson L, Shibre T: Khat chewing in persons with severe mental illness in Ethiopia: a qualitative study exploring perspectives of patients and caregivers. Transcult Psychiatry 2011, 48:455-472.
• [32]Arana GW: An Overview of Side Effects Caused by Typical Antipsychotics. J Clin Psychiatry 2000, 61(Suppl 8):5-11.
• [33]Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F: Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). Br J Psychiatry 2011, 199:467-472.
• [34]Hanlon C, Tesfaye M, Wondimagegn D, Shibre T: Ethical and professional challenges in mental health care in low- and middle-income countries. Int Rev Psychiat 2010, 22:245-251.
• [35]Srinivasan TN, Thara R: At issue: management of medication noncompliance in schizophrenia by families in India. Schizophr Bull 2002, 28:531-535.
• [36]Latha K: The Noncompliant Patient in Psychiatry: the Case For and Against Covert/Surreptitious Medication. Mens Sana Monogr 2010, 8:96-121.
• [37]Shibre T, Medhin G, Teferra S, Wakwoya A, Berhanu E, Abdulahi A, Alem A, Fekadu A: Predictors of carer-burden in schizophrenia: a five-year follow-up study in Butajira, Ethiopia. Ethiop Med J 2012, 50:125-133.
• [38]Carder PC, Vuckovic N, Green CA: Negotiating medications: patient perceptions of long-term medication use. J Clin Pharm Ther 2003, 28:409-417.
• [39]Shibre T, Negash A, Kullgren G, Kebede D, Alem A, Fekadu A, Fekadu D, Medhin G, Jacobsson L: Perception of stigma among family members of individuals with schizophrenia and major affective disorders in rural Ethiopia. Soc Psych Psych Epid 2001, 36:299-303.
• [40]Amador XF, Strauss DH: Poor insight in schizophrenia. Psychiat Quart 1993, 64:305-318.
• [41]Lysaker PH, Clements CA, Plascak-Hallberg CD, Knipscheer SJ, Wright DE: Insight and Personal Narratives of Illness in Schizophrenia. Psychiatry 2002, 65:197-206.
• [42]Bartko G, Herczeg I, Zador G: Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988, 77:74-76.
• [43]Lysaker PH, Buck KD, Salvatore G, Popolo R, Dimaggio G: Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches. Expert Rev Neurother 2009, 9:1035-43.
• [44]Lysaker PH, Dimaggio G, Buck KD, Callaway SS, Salvatore G, Carcion A, Nicolò G, Stanghellini G: Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness. Compr Psychiat 2011, 52:253-260.
• [45]Nageotte C, Sullivan G, Duan N, Camp PL: Medication compliance among the seriously mentally ill in a public mental health system. Soc Psych Psych Epid. 1997, 32:49-56.
• [46]Ruscher SM, de Wit R, Mazmanian D: Psychiatric patients’ attitudes about medication and factors affecting noncompliance. Psychiatr Serv 1997, 48:82-85.
• [47]Velligan DI, Lam F, Ereshefsky L, Miller AL: Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003, 54:665-667.
• [48]Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004, 30:255-264.
• [49]Frank AF, Gunderson JG: The role of the therapeutic alliance in the treatment of schizophrenia relationship to course and outcome. Arch Gen Psychiatry 1990, 47:228-236.
• [50]Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C: Attitudes toward antipsychotic medication the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005, 62:717-724.
• [51]Hardeman SM, Harding RK, Narasimhan M: Simplifying adherence in schizophrenia. Psychiat Serv 2010, 61:405-408.
• [52]World Health Organization & Mental Health and Poverty Project: Mental health and development: targeting people with mental health conditions as a vulnerable group. Geneva: UN World Health Organization; 2010.
• [53]Ministry of Health Federal Democratic Republic of Ethiopia: Country Progress Report on HIV/AIDS Response 2012. Addis Ababa: Ethiopia MOH; 2012.